At a glance
- Originator Alcon
- Class
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 03 Dec 2003 No development reported - Preclinical for Glaucoma in USA (unspecified route)
- 20 Sep 2001 Preclinical development for Glaucoma in USA (Unknown route)